Tehran: In the report, WhartoCell is introduced as an allogeneic, off-the-shelf cell-based therapeutic product derived from umbilical cord-derived mesenchymal stem cells (MSCs), developed with the aim of advancing innovative cell therapy approaches for the treatment of joint disorders and osteoarthritis.

According to Islamic Republic News Agency, MedPath, an international specialized platform focused on health information as well as the discovery and analysis of clinical-trial data, has highlighted the development pathway of WhartoCell in Iran and the role of Royan Institute in this scientific and technological achievement. The platform aggregates and structures clinical-trial information and health-related data from diverse scientific sources and international registries.

The development of WhartoCell exemplifies Royan Institute's approach to translating advances in cellular and molecular sciences into applicable technologies and innovative medical products. This translational pathway has its origins in basic research and has progressed through preclinical and clinical studies, process development and manufacturing, and the relevant regulatory pathways, bringing the product closer to therapeutic application.

This achievement further demonstrates Royan Institute's capacity to advance sophisticated cellular technologies and to facilitate the transition from knowledge generation toward the development of cell therapy products with potential for clinical-scale application.

Lotfipanah, Director of Public Relations and International Affairs at Royan Institute, stated: 'The publication of this report on an international specialized health platform, alongside Royan Institute's scientific and research activities, reflects the growing international visibility of Iran's scientific achievements in the fields of medical science and emerging health technologies.'

He further noted: 'Throughout more than three decades of activity, Royan Institute has established itself as one of the country's leading centers in reproductive medicine, stem cell science, regenerative medicine, and biotechnology, and has sought to pursue the continuum of 'research, technology, and service delivery' as an integrated and interconnected value chain.'

The recognition of WhartoCell as a cell-based therapeutic product by specialized international sources and platforms, including MedPath, represents an opportunity to showcase Iran's scientific and technological capabilities and to further strengthen Royan Institute's engagement with the global scientific and technological community.